Novo Nordisk to Sell Weight-Loss Drugs Through Hims & Hers Platform

Novo Nordisk dismissed its patent infringement lawsuit against Hims & Hers following an agreement allowing the telehealth platform to sell Novo's weight-loss drugs. The pharmaceutical company reserved rights to pursue future legal action if needed. The settlement enables Hims & Hers to distribute Novo's obesity medications through its digital health platform, resolving the intellectual property dispute between the companies.